Cargando…

Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma

We herein report the case of a 52-year-old man with stage IV lung adenocarcinoma. The patient was negative for epidermal growth factor receptor (EGFR) mutations and echinoderm microtubule-associated protein-like 4 (EML4) /anaplastic lymphoma kinase (ALK) rearrangement. He was treated with nivolumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakahara, Yoshiro, Fukui, Tomoya, Shirasawa, Masayuki, Harada, Shinya, Kusuhara, Seiichiro, Takakura, Akira, Yokoba, Masanori, Mitsufuji, Hisashi, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Masuda, Noriyuki, Inukai, Madoka, Sekiguchi, Tomoko, Naoki, Katsuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262697/ https://www.ncbi.nlm.nih.gov/pubmed/29877291 http://dx.doi.org/10.2169/internalmedicine.9884-17

Ejemplares similares

Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease
por: Igawa, Satoshi, et al.
Publicado: (2018)

Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2018)

Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2019)

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
por: Igawa, Satoshi, et al.
Publicado: (2021)

Questionnaire survey on patient awareness of invasive rebiopsy in advanced non‐small cell lung cancer
por: Fukui, Tomoya, et al.
Publicado: (2019)

Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study
por: Igawa, Satoshi, et al.
Publicado: (2019)

Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer
por: Igawa, Satoshi, et al.
Publicado: (2020)

Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab
por: Fukui, Tomoya, et al.
Publicado: (2020)

Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2016)

Endobronchial involvement of mantle cell lymphoma: A case report
por: Katono, Ken, et al.
Publicado: (2016)

Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study
por: Ono, Taihei, et al.
Publicado: (2019)

Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia
por: Shirasawa, Masayuki, et al.
Publicado: (2019)

The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Akazawa, Yuki, et al.
Publicado: (2023)

Pneumothorax during Pemetrexed Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report and Literature Review
por: Nakahara, Yoshiro, et al.
Publicado: (2017)

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status
por: Igawa, Satoshi, et al.
Publicado: (2018)

Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature
por: Nakahara, Yoshiro, et al.
Publicado: (2017)

Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan
por: Ryuge, Shinichiro, et al.
Publicado: (2009)

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation
por: Niwa, Hideyuki, et al.
Publicado: (2018)

Successful Chemotherapy with Nab-Paclitaxel in a Heavily Treated Non-Small Cell Lung Cancer Patient: A Case Report
por: Ishihara, Mikiko, et al.
Publicado: (2014)

Amrubicin monotherapy for elderly patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective study
por: Sone, Hideyuki, et al.
Publicado: (2018)

The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer
por: Kasajima, Masashi, et al.
Publicado: (2023)

Comparison between quantitative computed tomography, scintigraphy, and anatomical methods for prediction of postoperative FEV(1) and DLCO: effects of chronic obstructive pulmonary disease status and resected lobes
por: Yokoba, Masanori, et al.
Publicado: (2020)

Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017
por: Nakahara, Yoshiro, et al.
Publicado: (2019)

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer
por: Fukui, Tomoya, et al.
Publicado: (2016)

Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring BRAF V600E Mutation
por: Yagami, Yuri, et al.
Publicado: (2022)

Circulating tumor cells as a prognostic factor in patients with small cell lung cancer
por: IGAWA, SATOSHI, et al.
Publicado: (2014)

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)
por: Fukui, Tomoya, et al.
Publicado: (2022)

A Case of Synchronous Occurrence of Intracranial Germinoma and Systemic Sarcoidosis
por: HYAKUTAKE, Yuri, et al.
Publicado: (2021)

Differential response of adipose tissue gene and protein expressions to 4‐ and 8‐week administration of β‐guanidinopropionic acid in mice
por: Kato, Hisashi, et al.
Publicado: (2018)

Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report
por: Niwa, Hideyuki, et al.
Publicado: (2018)

Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin
por: Yamamoto, Michiko, et al.
Publicado: (2009)

Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment
por: Tada, Kouki, et al.
Publicado: (2022)

Prognostic significance of IMMT expression in surgically‐resected lung adenocarcinoma
por: Hiyoshi, Yasuhiro, et al.
Publicado: (2019)

An extremely rare case of nivolumab‐associated macroscopic duodenitis with spontaneous regression
por: Akizawa, Takatora, et al.
Publicado: (2020)

Effective treatment of gallbladder neuroendocrine carcinoma with nivolumab
por: Kanda, Shinichiro, et al.
Publicado: (2023)

Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604
por: Misumi, Yuki, et al.
Publicado: (2017)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Successful Chemotherapy with Carboplatin and S-1 for Thymic Carcinoma: A Case Report
por: Igawa, Satoshi, et al.
Publicado: (2013)

Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study
por: Sano, Akihiko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_maoq702r3lr0g6neq85lu3dd72